IP Library Granted Patent US 12,703,706
Granted Patent B2
US 12,703,706 · App. 18/256,130 · Granted Aug 11, 2026

Anthelmintic compounds comprising a thienopyridine structure

Inventors: Michael Berger (Wiesbaden, DE); Michael Linder (Ingelheim, DE); Carolin Schneider (Hofheim, DE); Janina Tänzler (Nierder-Olm, DE); Ulrich Sondern (Dortmund, DE)
Assignee: Intervet Inc.
C07D497/04A61P33/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,703,706
App. No.
18/256,130
Filed
Jun 6, 2023
Granted
Aug 11, 2026
Kind
B2
Art Unit
1626
USPC
514/301
Abstract

The present invention relates to new anthelmintic compounds. These compounds can for example be used in the treatment of the kind of worm disease caused by helminths such as Dirofilaria , in particular Dirofilaria immitis.

Claims (283)

1 . Compound of Formula (I)

wherein

R 1 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, C 1-6 -alkylmercapto, halogen, cyano, nitro, hydroxy, mercapto, NR 2 R 3 , COOH, C(═O)OR 4 , SR 4 , SOR 4 , SO 2 R 4 , SO 2 NR 5 R 6 and C(═O)NR 5 R 6 ,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy or C 1-6 -alkylmercapto, is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, C 1-6 -alkylmercapto, halogen, cyano, nitro, hydroxy, mercapto, NR 2′ R 3′ , C(═O)OR 4′ , SR 4′ , SOR 4′ , SO 2 R 4′ , SO 2 NR 5′ R 6′ and C(═O)NR 5′ R 6′ ,

R 2 and R 3 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1-6 -alkyl substituted with C 3-10 -cycloalkyl, C 1-6 -alkyl substituted with 5- to 10-membered heterocyclyl, C 1-6 -alkyl substituted with C 6-10 -aryl and C 1-6 -alkyl substituted with 5- to 10-membered heteroaryl, or

R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1-6 -alkyl substituted with C 3-10 -cycloalkyl, C 1-6 -alkyl substituted with 5- to 10-membered heterocyclyl, C 1-6 -alkyl substituted with C 6-10 -aryl or C 1-6 -alkyl substituted with 5- to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, carbonyl, halogen, cyano, hydroxy, mercapto, NR 2″ R 3″ , C(═O)OR 4″ , SR 4″ , SOR 4 , SO 2 R 4″ , SO 2 NR 5″ R 6″ and C(═O)NR 5″ R 6″ ,

R 4 , R 5 and R 6 are independently selected from hydrogen and C 1-6 -alkyl,

R 2′ , R 3′ , R 4′ , R 5′ and R 6′ are independently selected from hydrogen and C 1-6 -alkyl,

R 2″ , R 3″ , R 4″ , R 5″ and R 6″ are independently selected from hydrogen and C 1-6 -alkyl,

R 7 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 4- to 10-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, C 1-6 -alkylmercapto, halogen, cyano, nitro, hydroxy, mercapto, NR 8 R 9 , COOH, C(═O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 , SO 2 NR 11 R 12 and C(═O)NR 11 R 12 ,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 4- to 10-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy or C 1-6 -alkylmercapto, is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, C 1-6 -alkylmercapto, halogen, cyano, nitro, hydroxy, mercapto, oxo, NR 8′ R 9′ , C(═O)OR 10′ , SR 10′ , SOR 10′ , SO 2 R 10′ , SO 2 NR 11′ R 12′ and C(═O)NR 11′ R 12′ ,

R 8 and R 9 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1-6 -alkyl substituted with C 3-10 -cycloalkyl, C 1-6 -alkyl substituted with 5- to 10-membered heterocyclyl, C 1-6 -alkyl substituted with C 6-10 -aryl and C 1-6 -alkyl substituted with 5- to 10-membered heteroaryl, or

R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1-6 -alkyl substituted with C 3-10 -cycloalkyl, C 1-6 -alkyl substituted with 5- to 10-membered heterocyclyl, C 1-6 -alkyl substituted with C 6-10 -aryl or C 1-6 -alkyl substituted with 5- to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, carbonyl, halogen, cyano, hydroxy, mercapto, NR 8″ R 9″ , C(═O)OR 10″ , SR 10″ , SOR 10″ , SO 2 R 10″ , SO 2 NR 11″ R 12″ and C(═O)NR 11″ R 12″ ,

R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6 -alkyl,

R 8′ , R 9′ , R 10′ , R 11′ and R 12′ are independently selected from hydrogen and C 1-6 -alkyl,

R 8″ , R 9″ , R 10″ , R 11″ and R 12″ are independently selected from hydrogen and C 1-6 -alkyl,

R 13 is hydrogen or C 1-3 alkyl,

R 14 is hydrogen, C 1-3 alkyl, C 1-3 alkoxy, NR 14′ R 14″ , wherein R 14′ and R 14″ are independently C 1-3 -alkyl or

R 13 and R 14 together with the atoms to which they are attached form a 5 or 6-carbon atoms containing saturated ring, wherein the saturated ring is optionally substituted with one or more C 1-3 -alkyl or ═O, and/or wherein one or more of the ring-forming carbon atoms are optionally replaced by —NH—, —O—, —S(O)—, —S(O) 2 — or —S—, or

R 13 and R 14 together with the atoms to which they are attached form a 5 or 6-carbon atoms containing unsaturated ring, wherein the unsaturated ring is optionally substituted with one or more C 1-3 -alkyl, and/or wherein one or more of the ring-forming carbon atoms are optionally replaced by —NH—, —N═, ═N—, —O— or —S—,

A1 is N or CR 15 , wherein R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 15′ R 15″ , wherein R 15′ and R 15″ are independently C 1-3 -alkyl,

A2 is N or CR 16 , wherein R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 16′ R 16″ , wherein R 16′ and R 16″ are independently C 1-3 -alkyl,

A3 is N or CR 17 , wherein R 17 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 17′ R 17″ , wherein R 17 and R 17″ are independently C 1-3 -alkyl,

A4 is N or CR 18 , wherein R 18 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy, or NR 18′ R 18″ , wherein R 18′ and R 18″ are independently C 1-3 -alkyl,

R 19 is independently selected from the group consisting of C 6-10 -aryl and 5- to 10-membered heteroaryl,

wherein each C 6-10 -aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 2-6 -alkenyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, C 1-6 -alkylmercapto, halogen, cyano, nitro, hydroxy, mercapto, NR 20 R 21 , C(═O)OR 22 , SR 22 , SOR 22 , SO 2 R 22 , SO 2 NR 23 R 24 and C(═O)NR 23 R 24 ,

R 20 and R 21 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 3-10 -cycloalkyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1 -C 6 -alkyl substituted with C 6-10 -aryl, C 1-6 -alkyl substituted with 5- to 10-membered heteroaryl, or

R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy or C 1-6 -alkylmercapto or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of

C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, carbonyl, halogen, cyano, hydroxy, mercapto, NR 20′ R 21′ , C(═O)OR 22′ , SR 22′ , SOR 22′ , SO 2 R 22′ , SO 2 NR 23′ R 24′ and C(═O)NR 23′ R 24′ ,

R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6 -alkyl,

R 20′ , R 21′ , R 22′ , R 23′ and R 24′ are independently selected from hydrogen and C 1-6 -alkyl,

R 25 is independently selected from hydrogen and C 1-6 -alkyl,

or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph, prodrug and mixtures thereof.

2 . The compound according to claim 1 , wherein R 1 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 , C(═O)OR 4 and C(═O)NR 5 R 6 ,

wherein each C 1-6 -alkyl or C 1-6 -alkoxy is optionally substituted with one or more substituents independently selected from the group consisting of

C 1-6 -alkyl, C 1-6 -alkoxy, halogen, cyano, nitro, hydroxy and NR 2′ R 3′ ,

R 2 and R 3 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 3-10 -cycloalkyl, C 6-10 -aryl and 5 to 10-membered heteroaryl, or

R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O,

wherein each C 1-6 -alkyl, C 3-10 -cycloalkyl, C 6-10 -aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 3-10 -cycloalkyl and C 1-6 -alkoxy,

R 4 , R 5 and R 6 are independently selected from hydrogen and C 1-6 -alkyl,

R 2′ and R 3′ are independently selected from hydrogen and C 1-6 -alkyl.

3 . The compound according to claim 1 , wherein R 1 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy and halogen,

wherein each C 1-6 -alkyl or C 1-6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 1-6 -alkoxy, halogen, cyano, hydroxy and NR 2′ R 3′ ,

wherein R 2′ and R 3′ are independently selected from hydrogen and C 1-3 -alkyl.

4 . The compound according to claim 1 , wherein R 1 is independently selected from the group consisting of

hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride.

5 . The compound according to claim 1 , wherein R 7 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 3-10 -cycloalkyl, 4- to 10 membered heterocyclyl, C 1-6 -alkoxy, halogen, cyano, hydroxy, NR 8 R 9 , C(═O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 and C(═O)NR 11 R 12 ,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, C 3-10 -cycloalkyl, 4- to 10 membered heterocyclyl or C 1-6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 3-10 -cycloalkyl, 5- to 10 membered heterocyclyl, C 1-6 -alkoxy, halogen, cyano, hydroxy, oxo, NR 8′ R 9′ , C(═O)OR 10′ , and C(═O)NR 11′ R 12′ ,

R 8 and R 9 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 3-10 -cycloalkyl, C 6-10 -aryl, 5- to 10 membered heterocyclyl and 5- to 10 membered heteroaryl, or

R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O,

wherein each C 1-6 -alkyl, C 3-10 -cycloalkyl, C 6-10 -aryl, 5- to 10 membered heterocyclyl, and 5- to 10 membered heteroaryl or the heterocyclic ring formed by

R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 1-6 -alkoxy, halogen, cyano, hydroxy, NR 8″ R 9″ , C(═O)—OR 10″ and C(═O)NR 11″ R 12″ ;

R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6 -alkyl,

R 8′ , R 9′ , R 10′ , R 11′ and R 12′ are independently selected from hydrogen and C 1-6 -alkyl,

R 8″ , R 9″ , R 10″ , R 11″ and R 12″ are independently selected from hydrogen and C 1-6 -alkyl.

6 . The compound according to claim 1 , wherein R 7 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, 4- to 10 membered heterocyclyl, C 1-6 -alkoxy, hydroxy, NR 8 R 9 , C(═O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 and C(═O)NR 11 R 12 ,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, 4- to 10 membered heterocyclyl or C 1-6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, 5- to 10 membered heterocyclyl, C 1-6 -alkoxy, halogen, cyano, hydroxy, oxo, NR 8′ R 9′ , C(═O)OR 10′ and C(═O)NR 11′ R 12′ ,

R 8 and R 9 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 3-6 -cycloalkyl, C 6-10 -aryl, and 5- to 10 membered heteroaryl, or

R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O,

wherein the C 1-6 -alkyl, C 6-10 -aryl, and 5- to 10 membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 1-6 -alkoxy, hydroxy and NR 8″ R 9″ ,

R 10 , R 11 and R 12 are independently selected from hydrogen or C 1-6 -alkyl,

R 8′ , R 9′ , R 10′ , R 11′ and R 12′ are independently selected from hydrogen or C 1-6 -alkyl,

R 8″ are R 9″ are independently selected from hydrogen or C 1-6 -alkyl.

7 . The compound according to claim 1 , wherein R 7 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, 4- to 10 membered heterocyclyl, C 1-6 -alkoxy, NR 8 R 9 ,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, 4- to 10 membered heterocyclyl or C 1-6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 1-6 -alkoxy, and halogen,

R 8 and R 9 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 3-6 -cycloalkyl,

wherein the C 1-6 -alkyl, or C 3-6 -cycloalkyl is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 1-6 -alkoxy, and hydroxy.

8 . The compound according to claim 1 , wherein

R 13 and R 14 together with the atoms to which they are attached form a 5 or 6-carbon atoms containing saturated ring, wherein the saturated ring is optionally substituted with one or more C 1-3 -alkyl or ═O, and/or wherein one or more of the ring-forming carbon atoms are optionally replaced by —NH—, —O—, —S(O)—, —S(O) 2 — or —S—, or

R 13 and R 14 together with the atoms to which they are attached form a 5 or 6-carbon atoms containing unsaturated ring, wherein the unsaturated ring is optionally substituted with one or more C 1-3 -alkyl, and/or wherein one or more of the ring-forming carbon atoms are optionally replaced by —NH—, —N═, ═N—, —O— or —S—,

A1 is N or CR 15 , wherein R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15′ R 15″ , wherein R 15′ and R 15″ are independently C 1-3 -alkyl,

A2 is N or CR 16 , wherein R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16′ R 16″ , wherein R 16′ and R 16″ are independently C 1-3 -alkyl,

A3 is N or CR 17 , wherein R 17 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15′ R 15″ , wherein R 15′ and R 15″ are independently C 1-3 -alkyl,

A4 is N or CR 18 , wherein R 18 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 15′ R 15″ , wherein R 15′ and R 15″ are independently C 1-3 -alkyl.

9 . The compound according to claim 1 , wherein

R 13 and R 14 together with the atoms to which they are attached form a 5 or 6-carbon atoms containing saturated ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by —NH—, —O— or —S—, or

R 13 and R 14 together with the atoms to which they are attached form a 5 or 6-carbon atoms containing unsaturated ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by —NH—, —N═, ═N—, —O— or —S—,

A1 is CR 15 , wherein R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15′ R 15″ wherein R 15′ and R 15″ are independently C 1-3 -alkyl,

A2 is CR 16 , wherein R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16′ R 16″ , wherein R 16′ and R 16″ are independently C 1-3 -alkyl,

A3 is CR 17 , wherein R 17 is hydrogen,

A4 is CR 18 , wherein R 18 is hydrogen.

10 . The compound according to claim 1 , wherein

R 13 and R 14 together with the atoms to which they are attached form a 5 or 6-carbon atoms containing saturated ring, wherein one or more of the ring-forming carbon atoms are optionally replaced by —NH—, —O— or —S—,

A1 is CR 15 , wherein R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15′ R 15″ , wherein R 15′ and R 15″ are independently C 1-3 -alkyl,

A2 is CR 16 , wherein R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16′ R 16″ , wherein R 16′ and R 16″ are independently C 1-3 -alkyl,

A3 is CR 17 , wherein R 17 is hydrogen,

A4 is CR 18 , wherein R 18 is hydrogen.

11 . The compound according to claim 1 , wherein none, one or two of residues A1, A2, A3 and A4 is N.

12 . The compound according to claim 1 , wherein

R 19 is independently selected from the group consisting of

C 6-10 -aryl and 5- to 10-membered heteroaryl,

wherein each C 6-10 -aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, halogen, cyano, nitro, hydroxy, NR 20 R 21 , C(═O)OR 22 and C(═O)NR 23 R 24 ,

R 20 and R 21 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 3-10 -cycloalkyl and C 6-10 -aryl or

R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O;

wherein each C 1-6 -alkyl, C 3-10 -cycloalkyl, C 1-6 -alkoxy, or C 6-10 -aryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of

C 1-6 -alkyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, halogen, cyano, hydroxy, NR 20′ R 21′ , C(═O)OR 22′ and C(═O)NR 23′ R 24′

R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6 -alkyl,

R 20′ , R 21′ , R 22′ , R 23′ and R 24′ are independently selected from hydrogen and C 1-6 -alkyl.

13 . The compound according to claim 1 , wherein R 19 is independently selected from the group consisting of

C 6-10 -aryl and 5- to 10-membered heteroaryl

wherein each C 6-10 -aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 1-6 -alkoxy, halogen, cyano, nitro and hydroxy, wherein each C 1-6 -alkyl, C 1-6 -alkoxy, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, cyano, hydroxy, or wherein each C 1-6 -alkyl, C 1-6 -alkoxy, is optionally substituted with one or more halogen.

14 . The compound according to claim 1 , wherein R 19 is C 6-10 -aryl, wherein the C 6-10 -aryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, halogen, C 1-6 -alkoxy cyano and nitro wherein each C 1-6 -alkyl, C 1-6 -alkoxy is optionally substituted with one or more halogen.

15 . The compound according to claim 1 , wherein R 25 is hydrogen.

16 . Process for preparing the compound according to Formula (I)

comprising the step of

reacting a compound of Formula (A)

with a compound of Formula (B)

wherein R 1 , R 7 , R 13 , R 14 , A1, A2, A3, A4, R 19 and R 25 are defined as in claim 1 , to obtain the compound according to Formula (I).

17 . A Veterinary composition comprising

compound according to Formula (I) according to claim 1 , and

one or more physiologically acceptable excipient(s).

18 . A method of treating a disease caused by helminths which comprises administering to an animal a therapeutically effective amount of a compound according to Formula (I) according to claim 1 .

19 . A method of treating a disease according to claim 18 wherein the disease is a heartworm disease.

20 . A method of treating a disease caused by helminths which comprises administering to an animal, a therapeutically effective amount of the veterinary composition according to claim 17 .

21 . A method of treating a disease according to claim 20 wherein the disease is a heartworm disease.

22 . The compound according to claim 1 , wherein A1, A2, A3 and A4 are CH and is selected from compounds 3, 4, 6, 7, 10, 12, 13, 16, 32, 36, 39, 49, 53, 56, 62, 65, 68, 72, 102, 118, 128 as recited in the following table:

No

R 1

R 7

R 13

R 14

R 19

R 25

3

H

morpholin-4-yl

—CH 2 —CH 2 —

3,5-dichlorophenyl

H

4

H

morpholin-4-yl

—CH 2 —CH 2 —O—

2,3-dichlorophenyl

H

6

H

morpholin-4-yl

—CH 2 —CH 2 —

2,3-dichlorophenyl

H

7

H

dimethylamino

—CH 2 —CH 2 —O—

3,5-dichlorophenyl

H

10

H

dimethylamino

—CH 2 —CH 2 —O—

2,3-dichlorophenyl

H

12

H

dimethylamino

—CH 2 —CH 2 —

2,3-dichlorophenyl

H

13

H

morpholin-4-yl

—CH 2 —CH 2 —CH 2 —

2,3-dichlorophenyl

H

16

H

morpholin-4-yl

—CH 2 —CH 2 —

2,3,5-trifluorophenyl

H

32

H

morpholin-4-yl

—CH 2 —CH 2 —CH 2 —

3,5-dichlorophenyl

H

36

CH 3

dimethylamino

—CH 2 —CH 2 —O—

2,3-dichlorophenyl

H

39

H

3,3-difluoroazetidin-1-yl

—CH 2 —CH 2 —

2,3-dichlorophenyl

H

49

H

morpholin-4-yl

═CH—CH═CH—

3,5-dichlorophenyl

H

53

CH 3

dimethylamino

—CH 2 —CH 2 —O—

3,5-dichlorophenyl

H

56

CH 3

3,3-difluoroazetidin-1-yl

—CH 2 —CH 2 —O—

2,3-dichlorophenyl

H

62

CH 3

3-fluoroazetidin-1-yl

—CH 2 —CH 2 —O—

2,3-dichlorophenyl

H

65

CH 3

3-fluoroazetidin-1-yl

—CH 2 —CH 2 —O—

3,5-dichlorophenyl

H

68

CH 3

morpholin-4-yl

—CH 2 —CH 2 —O—

3,5-dichlorophenyl

H

72

CH 3

morpholin-4-yl

—CH 2 —CH 2 —O—

2,3-dichlorophenyl

H

102

CH 3

dimethylamino

—CH 2 —CH 2 —O—

2,3,5-trifluorophenyl

H

118

H

3-fluoroazetidin-1-yl

—CH 2 —CH 2 —

3,5-dichlorophenyl

H

128

H

morpholin-4-yl

—CH 2 —CH 2 —

3,5-difluorophenyl

H.

Assignments (4)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2023
From: BERGER, MICHAEL; LINDER, MICHAEL R.; SCHNEIDER, CAROLIN; TANZLER, JANINA; SONDERN, ULRICH
To: MSD ANIMAL HEALTH INNOVATION GMBH
Reel/Frame 063879/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2023
From: MSD ANIMAL HEALTH INNOVATION GMBH
To: INTERVET INTERNATIONAL B.V.
Reel/Frame 063879/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2023
From: INTERVET INTERNATIONAL B.V.
To: INTERVET INC.
Reel/Frame 063879/0774 →
Priority Claims (1)
EP 20213297 · Dec 11, 2020 · regional
Continuity (1)
Related Publication 20240043446A1 · Feb 8, 2024
References Cited (60)
US 5378679A · Nuebling et al. · 1995 [cited by applicant]
US 5399582A · Endris et al. · 1995 [cited by applicant]
US 5595991A · Shoop et al. · 1997 [cited by applicant]
US 5834260A · Byrne et al. · 1998 [cited by applicant]
US 5945317A · Byrne et al. · 1999 [cited by applicant]
US 5962499A · Meinke et al. · 1999 [cited by applicant]
US 6221894B1 · Meinke et al. · 2001 [cited by applicant]
US 7312248B2 · Meyer et al. · 2007 [cited by applicant]
US 7361689B2 · Shuster et al. · 2008 [cited by applicant]
US 8106212B2 · Jeschke et al. · 2012 [cited by applicant]
US 20040138449A1 · Larsen et al. · 2004 [cited by applicant]
US 20050182059A1 · Winzenberg et al. · 2005 [cited by applicant]
US 20060128779A1 · Winzenberg et al. · 2006 [cited by applicant]
US 20060281695A1 · Meyer et al. · 2006 [cited by applicant]
US 20200128830A1 · Kausch-Busies et al. · 2020 [cited by applicant]
EP 0539588A1 · 1993 [cited by applicant]
WO 1996029073A1 · 1996 [cited by applicant]
WO 2003059878A2 · 2003 [cited by applicant]
WO 2003059912A1 · 2003 [cited by applicant]
WO 2005123744A1 · 2005 [cited by applicant]
WO 2007115643A1 · 2007 [cited by applicant]
WO 2010053517A2 · 2010 [cited by applicant]
WO 2010075591A2 · 2010 [cited by applicant]
WO 2010129500A2 · 2010 [cited by applicant]
WO 2017178416A1 · 2017 [cited by applicant]
WO 2017192385A1 · 2017 [cited by applicant]
WO 2019170626A1 · 2019 [cited by applicant]
WO 2019197468A1 · 2019 [cited by applicant]
WO 2019201835A1 · 2019 [cited by applicant]
WO 2019206799A1 · 2019 [cited by applicant]
WO 2019215182A1 · 2019 [cited by applicant]
WO 2019215198A1 · 2019 [cited by applicant]
WO 2020053364A1 · 2020 [cited by applicant]
WO 2020053365A2 · 2020 [cited by applicant]
WO 2020070049A1 · 2020 [cited by applicant]
WO 2020079198A1 · 2020 [cited by applicant]
WO 2020094363A1 · 2020 [cited by applicant]
WO 2020131629A1 · 2020 [cited by applicant]
WO 2020169445A1 · 2020 [cited by applicant]
WO 2020193341A1 · 2020 [cited by applicant]
WO 2020201079A1 · 2020 [cited by applicant]
WO 2020201398A1 · 2020 [cited by applicant]
WO 2020208036A1 · 2020 [cited by applicant]
WO 2020212235A1 · 2020 [cited by applicant]
WO 2020219871A1 · 2020 [cited by applicant]
Higuchi, T., et al., “Pro-drugs as NovelDelivery Systems”, A.C.S. Symposium Series, 1987, 14, pp. 1-6. [cited by applicant]
Kokatla, Hari Prasad et al., Structure-Based Design of Novel Human Toll-like Receptor 8 Agonists, ChemMedChem, 2014, 719-723, 9. [cited by applicant]
Kotha, Sambasivarao et al., Recent applications of the Suzuki-Miyaura cross-coupling reaction in organic synthesis, Tetrahedron, 2002, 9633-9695, 58. [cited by applicant]
Pokhodylo, Nazariy T. et al., Facile and Efficient One-Pot Procedure for Thieno[2,3-e][1,2,3]triazolo[1,5-a] pyrimidines Preparation, Synthetic Communications, 2014, 1002-1006, 44:7. [cited by applicant]
Ponte, Cristiano G. et al., Selective, Direct Activation of High-Conductance, Calcium-Activated Potassium Channels Causes Smooth Muscle Relaxation, Molecular Pharmacology, 2012, 567-577, 81(4). [cited by applicant]
Belikov, V.G., Pharmaceutical Chemistry, Moscow MEDpress-inform, 4th Edition, 27-29, 2007. [cited by applicant]
Bernstein, J., Bioavailability, Polymorphism of molecular crystals, Ch. 7.3.2, 324-330, 2007. [cited by applicant]
Caira, Crystalline Polymorphism of organic compounds, Topics in Current Chemistry, 198, 163-208, 1998. [cited by applicant]
Dyson, G. and May, P., Chemistry of Synthetic Medicinal Substances, M: World, N/A, 12-19, 1964. [cited by applicant]
Kholodov, L.E. et al., Clinical Pharmacokinetics, Moscow, Medicine, N/A, 83-98, 134-138, 160, 378-380, 1985. [cited by applicant]
Knunyants, I.L. (Editor), Chemical Encyclopedic Dictionary, Moscow, Soviet Encyclopaedia, N/A, 130-131, 1983. [cited by applicant]
Kummerer, K., Pharmaceuticals in the environment, Annual Review of Environment and Resources, 35, 57-75, 2010. [cited by applicant]
Pinto M.A.L. et al., Thermoanalytical studies of carbamazepine: hydration/dehydration, thermal decomposition, and solid phase transitions, Brazilian Journal of Pharmaceutical Sciences, 50, 877-884 (English abstract), 20… [cited by applicant]
Sergeeva, P.V. (Sergeev, P.V.), A short course in molecular pharmacology, Mockba, N/A, 10, 1975. [cited by applicant]
Smirnova, I.G. et al., Optical Isomerism and Biological Activity of Pharmaceutical Preparations, Moscow University Chemistry Bulletin, 67(3), 95-102 (English translation of original Russian text—I.G. Smirnova, G.N. Gil'… [cited by applicant]